Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

M. Razzo, Beatrice; Midha, Shonali; J. Portuguese, Andrew; F. Grajales-Cruz, Ariel; De Menezes Silva Corraes, Andre; Costello, Patrick; Liu, Yuxin; S. Sperling, Adam; Nadeem, Omar; Dima, Danai; Banerjee, Rahul; J. Cowan, Andrew; Afrough, Aimaz; D. Anderson, Larry; Lieberman-Cribbin, Alex; Kaur, Gurbakhash; Goyal, Anmol; Atrash, Shebli; J. Ferreri, Christopher; M. Voorhees, Peter; Pasvolsky, Oren; C. Lee, Hans; K. Patel, Krina; L. Julian, Kelley; A. Forsberg, Peter; M. Herr, Megan; Chhabra, Saurabh; D. Parrondo, Ricardo; Lin, Yi; Chen, Anna; P. Susanibar-Adaniya, Sandra; Khouri, Jack; Raza, Shahzad; Anwer, Faiz; Vazquez-Martinez, Mariola; Castaneda Puglianini, Omar; W. Sborov, Douglas; A. Davis, James; Rossi, Adriana; Shune, Leyla; Bhurtel, Jenny; Hwang, Wei-Ting; K. Hansen, Doris; Sidana, Surbhi; L. Garfall, Alfred; Richard, Shambavi

doi:10.1158/2643-3230.bcd-24-0354

Public

Real-World Experience with Teclistamab for Relapsed/Refractory Multiple Myeloma from the US Myeloma Immunotherapy Consortium

Shared by NobleBlocks on Jul 9, 2025 • 12:00 AM UTC

Authors:

Beatrice M. Razzo

Shonali Midha

Andrew J. Portuguese

Abstract

Abstract Teclistamab is an anti-CD3-/B-cell maturation antigen (BCMA) bispecific antibody approved for use in relapsed/refractory multiple myeloma. We undertook a retrospective study of post-approval, real-world outcomes with teclistamab in the US Multiple Myeloma Immunotherapy Consortium. Among 509...

Discussions